News & articles

  • SEPTEMBER EDITION OF MPD LIFE

    Like the MPD Foundation, the United Kingdom’s MPD-Support has a free newsletter available to patients and other members of the MPD community. To download their latest edition of MPD Life click here.

    READ MORE

    INCYTE APPROVED BY FDA FOR SPECIAL PV PROTOCOL

    September 2010 The FDA has approved a special protocol for Incyte’s clinical trial for Polycythemia Vera patients. Their RESPONSE (Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care) is expected to enroll approximately… Read More »INCYTE APPROVED BY FDA FOR SPECIAL PV PROTOCOL

    READ MORE

    SANOFI-AVENTIS PURCHASES TARGEGEN, DEVELOPER OF DRUGS FOR MYELOPROLIFERATIVE DISORDERS

    TargeGen, producer of JAK2 inhibitor TG101348, was purchased on June 30 2010 by French pharmaceutical company Sanofi-Aventis. Sanofi-Aventis hopes to continue to develop drugs targeted at hematological malignancies. Clinical trials for TG101348 have completed enrollment. For the full press release click here.

    READ MORE

    ANNOUNCING CHALLENGE GRANT 2011

    The MPD Foundation is pleased to announce a Call for Proposals for its 2011 Challenge Grant Program. Worthy projects will advance the understanding of mechanisms of action in the MPD’s and/or contribute to accelerating the discovery and development of new treatments for MPD patients. The MPD Foundation is a private not-for-profit advocacy organization seeking to… Read More »ANNOUNCING CHALLENGE GRANT 2011

    READ MORE

    AMERICAN SOCIETY OF HEMATOLOGY CONVENTION 2009

    Each year the American Society of Hematology (ASH) hosts their annual convention, where researchers, doctors and organizations such as the MPD Foundation gather to discuss the ever changing world of blood disorders and learn about the progress of research. The MPD Foundation is pleased to once again host a booth at this year’s ASH convention.… Read More »AMERICAN SOCIETY OF HEMATOLOGY CONVENTION 2009

    READ MORE

    UPDATE ON THE MF CHALLENGE GRANT REVIEW

    On June 1st twelve experts on myelofibrosis, myeloproliferative neoplasms and fibrosis gathered around a table in a classroom at Northwestern University in Chicago. They were there to debate the merits of proposals received by the MPN Research Foundation and the Leukemia & Lymphoma Society for their MF Challenge initiative. The spirited discussion – lasting around 6 hours – ended with the… Read More »UPDATE ON THE MF CHALLENGE GRANT REVIEW

    READ MORE

    RUBEN MESA DISCUSSES RESEARCH AND SYMPOSIUM

    The MPN Research Foundation in collaboration with Patient Power have released a video of Dr. Ruben Mesa speaking about one of his current research projects. In 2011 Dr. Mesa was awarded a grant from the MPN Research Foundation to validate the MPN symptom assessment form for patients with Polycythemia Vera and Post-Polycythemia Vera Myelofibrosis. The… Read More »RUBEN MESA DISCUSSES RESEARCH AND SYMPOSIUM

    READ MORE

    TIM’S RUN MAINE

    September 15, 2015 Tim Flaherty was a firefighter for 33 years with the Portland Fire Department, who passed away August 30, 2011 at only 63 years old, following a courageous fight against Myelofibrosis. The MPN community lost a hero that day, and we lost a loving husband, father, grandfather and best buddy to many. In… Read More »TIM’S RUN MAINE

    READ MORE

    WHY DON’T JAK INHIBITORS REDUCE THE DISEASE BURDEN IN MYELOFIBROSIS?

    This article was featured in the MPN Update Newsletter. If you’d like to receive a free copy click here. By MPN Research Foundation Scientific Advisor John Crispino, PhD With the discovery of JAK2 mutations and the recent approval of Ruxolitinib for individuals with myelofibrosis, there is a great deal of excitement and hope. However, there is also concern… Read More »WHY DON’T JAK INHIBITORS REDUCE THE DISEASE BURDEN IN MYELOFIBROSIS?

    READ MORE

    THE YEAR IN PV, ET AND MF

    Since our letter to you this summer, progress has been made in clinical trials for each MPN disease group (ET, PV and MF), the promise of which is that more treatment options for all MPN patients are on the horizon. In addition, academic scientists are beginning to understand how JAK inhibitors work while at the… Read More »THE YEAR IN PV, ET AND MF

    READ MORE

    1 37 38 39 40 41 43
  • Join the MPN Research community

    Be the first to know about the latest news and advancements.
    What are the latest developments in MPN Research?